Highly prevalent TERT promoter mutations in aggressive thyroid cancers

Xiaoli Liu, Justin Bishop, Yuan Shan, Sara Pai, Dingxie Liu, Avaniyapuram Kannan Murugan, Hui Sun, Adel K. El-Naggar, Mingzhao Xing

Research output: Contribution to journalArticle

298 Citations (Scopus)

Abstract

Mutations 1 295 228 C > T and 1 295 250 C > T (termed C228T and C250T respectively), corresponding to -124 C > T and -146 C > T from the translation start site in the promoter of the telomerase reverse transcriptase (TERT) gene, have recently been reported in human cancers, but not in thyroid cancers yet. We explored these mutations in thyroid cancers by genomic sequencing of a large number of primary tumor samples. We found the C228T mutation in 0 of 85 (0.0%) benign thyroid tumors, 30 of 257 (11.7%) papillary thyroid cancers (PTC), 9 of 79 (11.4%) follicular thyroid cancers (FTC), 3 of 8 (37.5%) poorly differentiated thyroid cancers (PDTC), 23 of 54 (42.6%) anaplastic thyroid cancers (ATC), and 8 of 12 (66.7%) thyroid cancer cell lines. The C250T mutation was uncommon, but mutually exclusive with the C228T mutation, and the two mutations were collectively found in 11 of 79 (13.9%) FTC, 25 of 54 (46.3%) ATC, and 11 of 12 (91.7%) thyroid cancer cell lines. Among PTC variants, the C228T mutation was found in 4 of 13 (30.8%) tall-cell PTC (TCPTC), 23 of 187 (12.3%) conventional PTC, and 2 of 56 (3.6%) follicular variant PTC samples. No TERT mutation was found in 16 medullary thyroid cancer samples. The C228T mutation was associated with the BRAF V600E mutation in PTC, being present in 19 of 104 (18.3%) BRAF mutation-positive PTC vs 11 of 153 (7.2%) the BRAF mutation-negative PTC samples (P = 0.0094). Conversely, BRAF mutation was found in 19 of 30 (63.3%) C228T mutation-positive PTC vs 85 of 227 (37.4%) C228T mutation-negative PTC samples (P = 0.0094). We thus for the first time, to our knowledge, demonstrate TERT promoter mutations in thyroid cancers, that are particularly prevalent in the aggressive thyroid cancers TCPTC, PDTC, ATC and BRAF mutation-positive PTC, revealing a novel genetic background for thyroid cancers.

Original languageEnglish (US)
Pages (from-to)603-610
Number of pages8
JournalEndocrine-Related Cancer
Volume20
Issue number4
DOIs
StatePublished - Aug 1 2013

Fingerprint

Telomerase
Thyroid Neoplasms
Mutation
Papillary Thyroid cancer
Cell Line
Neoplasms
Factor IX

Keywords

  • BRAF V600e mutation
  • Telomerase reverse transcriptase
  • TERT promoter mutations
  • Thyroid cancers
  • Thyroid tumorigenesis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research

Cite this

Liu, X., Bishop, J., Shan, Y., Pai, S., Liu, D., Murugan, A. K., ... Xing, M. (2013). Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocrine-Related Cancer, 20(4), 603-610. https://doi.org/10.1530/ERC-13-0210

Highly prevalent TERT promoter mutations in aggressive thyroid cancers. / Liu, Xiaoli; Bishop, Justin; Shan, Yuan; Pai, Sara; Liu, Dingxie; Murugan, Avaniyapuram Kannan; Sun, Hui; El-Naggar, Adel K.; Xing, Mingzhao.

In: Endocrine-Related Cancer, Vol. 20, No. 4, 01.08.2013, p. 603-610.

Research output: Contribution to journalArticle

Liu, X, Bishop, J, Shan, Y, Pai, S, Liu, D, Murugan, AK, Sun, H, El-Naggar, AK & Xing, M 2013, 'Highly prevalent TERT promoter mutations in aggressive thyroid cancers', Endocrine-Related Cancer, vol. 20, no. 4, pp. 603-610. https://doi.org/10.1530/ERC-13-0210
Liu, Xiaoli ; Bishop, Justin ; Shan, Yuan ; Pai, Sara ; Liu, Dingxie ; Murugan, Avaniyapuram Kannan ; Sun, Hui ; El-Naggar, Adel K. ; Xing, Mingzhao. / Highly prevalent TERT promoter mutations in aggressive thyroid cancers. In: Endocrine-Related Cancer. 2013 ; Vol. 20, No. 4. pp. 603-610.
@article{8b4856de99d242438f4f6b8934af75d7,
title = "Highly prevalent TERT promoter mutations in aggressive thyroid cancers",
abstract = "Mutations 1 295 228 C > T and 1 295 250 C > T (termed C228T and C250T respectively), corresponding to -124 C > T and -146 C > T from the translation start site in the promoter of the telomerase reverse transcriptase (TERT) gene, have recently been reported in human cancers, but not in thyroid cancers yet. We explored these mutations in thyroid cancers by genomic sequencing of a large number of primary tumor samples. We found the C228T mutation in 0 of 85 (0.0{\%}) benign thyroid tumors, 30 of 257 (11.7{\%}) papillary thyroid cancers (PTC), 9 of 79 (11.4{\%}) follicular thyroid cancers (FTC), 3 of 8 (37.5{\%}) poorly differentiated thyroid cancers (PDTC), 23 of 54 (42.6{\%}) anaplastic thyroid cancers (ATC), and 8 of 12 (66.7{\%}) thyroid cancer cell lines. The C250T mutation was uncommon, but mutually exclusive with the C228T mutation, and the two mutations were collectively found in 11 of 79 (13.9{\%}) FTC, 25 of 54 (46.3{\%}) ATC, and 11 of 12 (91.7{\%}) thyroid cancer cell lines. Among PTC variants, the C228T mutation was found in 4 of 13 (30.8{\%}) tall-cell PTC (TCPTC), 23 of 187 (12.3{\%}) conventional PTC, and 2 of 56 (3.6{\%}) follicular variant PTC samples. No TERT mutation was found in 16 medullary thyroid cancer samples. The C228T mutation was associated with the BRAF V600E mutation in PTC, being present in 19 of 104 (18.3{\%}) BRAF mutation-positive PTC vs 11 of 153 (7.2{\%}) the BRAF mutation-negative PTC samples (P = 0.0094). Conversely, BRAF mutation was found in 19 of 30 (63.3{\%}) C228T mutation-positive PTC vs 85 of 227 (37.4{\%}) C228T mutation-negative PTC samples (P = 0.0094). We thus for the first time, to our knowledge, demonstrate TERT promoter mutations in thyroid cancers, that are particularly prevalent in the aggressive thyroid cancers TCPTC, PDTC, ATC and BRAF mutation-positive PTC, revealing a novel genetic background for thyroid cancers.",
keywords = "BRAF V600e mutation, Telomerase reverse transcriptase, TERT promoter mutations, Thyroid cancers, Thyroid tumorigenesis",
author = "Xiaoli Liu and Justin Bishop and Yuan Shan and Sara Pai and Dingxie Liu and Murugan, {Avaniyapuram Kannan} and Hui Sun and El-Naggar, {Adel K.} and Mingzhao Xing",
year = "2013",
month = "8",
day = "1",
doi = "10.1530/ERC-13-0210",
language = "English (US)",
volume = "20",
pages = "603--610",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "Society for Endocrinology",
number = "4",

}

TY - JOUR

T1 - Highly prevalent TERT promoter mutations in aggressive thyroid cancers

AU - Liu, Xiaoli

AU - Bishop, Justin

AU - Shan, Yuan

AU - Pai, Sara

AU - Liu, Dingxie

AU - Murugan, Avaniyapuram Kannan

AU - Sun, Hui

AU - El-Naggar, Adel K.

AU - Xing, Mingzhao

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Mutations 1 295 228 C > T and 1 295 250 C > T (termed C228T and C250T respectively), corresponding to -124 C > T and -146 C > T from the translation start site in the promoter of the telomerase reverse transcriptase (TERT) gene, have recently been reported in human cancers, but not in thyroid cancers yet. We explored these mutations in thyroid cancers by genomic sequencing of a large number of primary tumor samples. We found the C228T mutation in 0 of 85 (0.0%) benign thyroid tumors, 30 of 257 (11.7%) papillary thyroid cancers (PTC), 9 of 79 (11.4%) follicular thyroid cancers (FTC), 3 of 8 (37.5%) poorly differentiated thyroid cancers (PDTC), 23 of 54 (42.6%) anaplastic thyroid cancers (ATC), and 8 of 12 (66.7%) thyroid cancer cell lines. The C250T mutation was uncommon, but mutually exclusive with the C228T mutation, and the two mutations were collectively found in 11 of 79 (13.9%) FTC, 25 of 54 (46.3%) ATC, and 11 of 12 (91.7%) thyroid cancer cell lines. Among PTC variants, the C228T mutation was found in 4 of 13 (30.8%) tall-cell PTC (TCPTC), 23 of 187 (12.3%) conventional PTC, and 2 of 56 (3.6%) follicular variant PTC samples. No TERT mutation was found in 16 medullary thyroid cancer samples. The C228T mutation was associated with the BRAF V600E mutation in PTC, being present in 19 of 104 (18.3%) BRAF mutation-positive PTC vs 11 of 153 (7.2%) the BRAF mutation-negative PTC samples (P = 0.0094). Conversely, BRAF mutation was found in 19 of 30 (63.3%) C228T mutation-positive PTC vs 85 of 227 (37.4%) C228T mutation-negative PTC samples (P = 0.0094). We thus for the first time, to our knowledge, demonstrate TERT promoter mutations in thyroid cancers, that are particularly prevalent in the aggressive thyroid cancers TCPTC, PDTC, ATC and BRAF mutation-positive PTC, revealing a novel genetic background for thyroid cancers.

AB - Mutations 1 295 228 C > T and 1 295 250 C > T (termed C228T and C250T respectively), corresponding to -124 C > T and -146 C > T from the translation start site in the promoter of the telomerase reverse transcriptase (TERT) gene, have recently been reported in human cancers, but not in thyroid cancers yet. We explored these mutations in thyroid cancers by genomic sequencing of a large number of primary tumor samples. We found the C228T mutation in 0 of 85 (0.0%) benign thyroid tumors, 30 of 257 (11.7%) papillary thyroid cancers (PTC), 9 of 79 (11.4%) follicular thyroid cancers (FTC), 3 of 8 (37.5%) poorly differentiated thyroid cancers (PDTC), 23 of 54 (42.6%) anaplastic thyroid cancers (ATC), and 8 of 12 (66.7%) thyroid cancer cell lines. The C250T mutation was uncommon, but mutually exclusive with the C228T mutation, and the two mutations were collectively found in 11 of 79 (13.9%) FTC, 25 of 54 (46.3%) ATC, and 11 of 12 (91.7%) thyroid cancer cell lines. Among PTC variants, the C228T mutation was found in 4 of 13 (30.8%) tall-cell PTC (TCPTC), 23 of 187 (12.3%) conventional PTC, and 2 of 56 (3.6%) follicular variant PTC samples. No TERT mutation was found in 16 medullary thyroid cancer samples. The C228T mutation was associated with the BRAF V600E mutation in PTC, being present in 19 of 104 (18.3%) BRAF mutation-positive PTC vs 11 of 153 (7.2%) the BRAF mutation-negative PTC samples (P = 0.0094). Conversely, BRAF mutation was found in 19 of 30 (63.3%) C228T mutation-positive PTC vs 85 of 227 (37.4%) C228T mutation-negative PTC samples (P = 0.0094). We thus for the first time, to our knowledge, demonstrate TERT promoter mutations in thyroid cancers, that are particularly prevalent in the aggressive thyroid cancers TCPTC, PDTC, ATC and BRAF mutation-positive PTC, revealing a novel genetic background for thyroid cancers.

KW - BRAF V600e mutation

KW - Telomerase reverse transcriptase

KW - TERT promoter mutations

KW - Thyroid cancers

KW - Thyroid tumorigenesis

UR - http://www.scopus.com/inward/record.url?scp=84882805198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882805198&partnerID=8YFLogxK

U2 - 10.1530/ERC-13-0210

DO - 10.1530/ERC-13-0210

M3 - Article

C2 - 23766237

AN - SCOPUS:84882805198

VL - 20

SP - 603

EP - 610

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 4

ER -